Generic placeholder image

Current Medical Imaging

Author(s): Wang Yinzhong, Tian Xiaoxue, Tian Jinhui, Yang Pengcheng, Liu Xiaoying and Lei Junqiang*

DOI: 10.2174/1573405617666210917124404

DownloadDownload PDF Flyer Cite As
Is Gadoxetic Acid Disodium (Gd-EOB-DTPA)-Enhanced Magnetic Resonance Imaging an Accurate Diagnostic Method for Hepatocellular Carcinoma? A Systematic Review with Meta-Analysis

Article ID: e170921196604 Pages: 15

  • * (Excluding Mailing and Handling)

Explore Articles
About Journal
For Authors
For Editors
For Reviewers

Abstract

Background: Gadolinium Ethoxybenzyl Diethylenetriamine Pentaacetic Acid (Gd- EOB-DTPA) has become a widely used liver-specific contrast agent worldwide, but its value and limitations as a diagnostic technique with Hepatocellular Carcinoma (HCC), have not been assessed.

Introduction: A review of the latest evidence available on the diagnostic value of Gd-EOB-DTPA- enhanced MRI for the evaluation of HCC is reported.

Methods: A systematic, comprehensive literature search was conducted with PubMed, Scopus, EMBASE, the Web of Science, the Cochrane Library, CNKI, vip, wanfangdata and CBM from inception to June 31, 2020. The QUADAS-2 tool was used to evaluate the quality of the included studies. Pooled Sensitivity (SEN), Pooled Specificity (SPE), pooled positive likelihood ratio (PLR), pooled negative likelihood ratio (NLR), pooled diagnostic odds ratio (dOR) and summary receiver operating characteristic (SROC) curves were calculated to assess the diagnostic value of the individual diagnostic tests.

Results: A total of 47 articles were included, involving a total of 6362 nodules in 37 studies based on per-lesion studies. There were 13 per-patient studies, including a total of 1816 patients. The results of the meta-analysis showed that the per-lesion studies pooled weighted values were SEN 0.90 [95% confidence interval (CI): 0.87-0.92], SPE 0.92 (95% CI: 0.90-0.94), PLR 11.6 (95% CI: 8.8-15.2), NLR 0.11 (95% CI: 0.09-0.14) and dOR 107.0 (95% CI: 74.0-155.0). The AUC of the SROC curve was 0.96. The per-patient studies pooled weighted values were SEN 0.84 [95% confidence interval (CI): 0.78-0.89], SPE 0.92 (95% CI: 0.88-0.94), PLR 10.4 (95% CI: 7.4-14.6), NLR 0.17 (95% CI: 0.12-0.24) and dOR 61.0 (95% CI: 42.0-87.0). The AUC of the SROC curve was 0.95 and subgroup analyses were performed.

Conclusion: The diagnostic value of Gd-EOB-DTPA for HCC was quantitatively evaluated in a per-lesion study and a per-patient study using a systematic review of the literature. A positive conclusion was drawn: Gd-EOB-DTPA-enhanced imaging is a valuable diagnostic technique for HCC. The size of the nodules and the selection of the imaging diagnostic criteria may affect the diagnostic sensitivity.

Keywords: Dual diagnostic tests, Meta-analysis, Gd-EOB-DTPA, hepatocellular carcinoma, HCC, gadoxetic acid disodium, primovist.

Graphical Abstract

[1]
Ferlay J, Colombet M, Soerjomataram I, et al. Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods. Int J Cancer 2019; 144(8): 1941-53.
[http://dx.doi.org/10.1002/ijc.31937] [PMID: 30350310]
[2]
Zhou M, Wang H, Zeng X, et al. Mortality, morbidity, and risk factors in China and its provinces, 1990-2017: A systematic analysis for the Global Burden of Disease Study 2017. Lancet 2019; 394(10204): 1145-58.
[http://dx.doi.org/10.1016/S0140-6736(19)30427-1] [PMID: 31248666]
[3]
Gadoxetate disodium: label and approval history. U.S. food and drug administration web site. 2010. Availalble from: http://www.accessdata.fda.gov /scripts/cder/drugsatfda/index.cfm?fuseaction=Search.Label_ApprovalHistory#apphist [Accessed September6, 2010]
[4]
Hamm B, Staks T, Mühler A, et al. Phase I clinical evaluation of Gd-EOB-DTPA as a hepatobiliary MR contrast agent: safety, pharmacokinetics, and MR imaging. Radiology 1995; 195(3): 785-92.
[http://dx.doi.org/10.1148/radiology.195.3.7754011] [PMID: 7754011]
[5]
Vogl TJ, Kümmel S, Hammerstingl R, et al. Liver tumors: comparison of MR imaging with Gd-EOB-DTPA and Gd-DTPA. Radiology 1996; 200(1): 59-67.
[http://dx.doi.org/10.1148/radiology.200.1.8657946] [PMID: 8657946]
[6]
Huppertz A, Balzer T, Blakeborough A, et al. Improved detection of focal liver lesions at MR imaging: multicenter comparison of gadoxetic acid-enhanced MR images with intraoperative findings. Radiology 2004; 230(1): 266-75.
[http://dx.doi.org/10.1148/radiol.2301020269] [PMID: 14695400]
[7]
Junqiang L, Yinzhong W, Li Z, et al. Gadoxetic acid disodium (Gd-EOBDTPA)-enhanced magnetic resonance imaging for the detection of hepatocellular carcinoma: A meta-analysis. J Magn Reson Imaging 2014; 39(5): 1079-87.
[http://dx.doi.org/10.1002/jmri.24354] [PMID: 25006627]
[8]
McInnes MDF, Moher D, Thombs BD, et al. Preferred reporting items for a systematic review and meta-analysis of diagnostic test accuracy studies: The PRISMA-DTA statement. JAMA 2018; 319(4): 388-96.
[http://dx.doi.org/10.1001/jama.2017.19163] [PMID: 29362800]
[9]
Battaglia M, Bucher H, Egger M, Grossenbacher F, Minder C, Pewsner D. The Bayes library of diagnostic studies and reviews. 2nd ed. Basel, Switzerland: University of Basel 2002.
[10]
Whiting PF, Rutjes AW, Westwood ME, et al. QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies. Ann Intern Med 2011; 155(8): 529-36.
[http://dx.doi.org/10.7326/0003-4819-155-8-201110180-00009] [PMID: 22007046]
[11]
Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003; 327(7414): 557-60.
[http://dx.doi.org/10.1136/bmj.327.7414.557] [PMID: 12958120]
[12]
Dwamena B, Sylvester R, Carlos R. MIDAS: Stata module for meta-analytical integration of diagnostic test accuracy studies.Statistical software components S456880. Department of economics, Boston College 2007.
[13]
Baird AJ, Amos GJ, Saad NF, Benson MD. Retrospective audit to determine the diagnostic accuracy of Primovist-enhanced MRI in the detection of hepatocellular carcinoma in cirrhosis with explant histopathology correlation. J Med Imaging Radiat Oncol 2013; 57(3): 314-20.
[http://dx.doi.org/10.1111/1754-9485.12038] [PMID: 23721140]
[14]
Ayuso C, Forner A, Darnell A, et al. Prospective evaluation of gadoxetic acid magnetic resonance for the diagnosis of hepatocellular carcinoma in newly detected nodules ≤2 cm in cirrhosis. Liver Int 2019; 39(7): 1281-91.
[http://dx.doi.org/10.1111/liv.14133] [PMID: 31077539]
[15]
Bashir MR, Gupta RT, Davenport MS, et al. Hepatocellular carcinoma in a North American population: Does hepatobiliary MR imaging with Gd-EOB-DTPA improve sensitivity and confidence for diagnosis? J Magn Reson Imaging 2013; 37(2): 398-406.
[http://dx.doi.org/10.1002/jmri.23818] [PMID: 23011874]
[16]
Besa C, Lewis S, Pandharipande PV, et al. Hepatocellular carcinoma detection: diagnostic performance of a simulated abbreviated MRI protocol combining diffusion-weighted and T1-weighted imaging at the delayed phase post gadoxetic acid. Abdom Radiol (NY) 2017; 42(1): 179-90.
[http://dx.doi.org/10.1007/s00261-016-0841-5] [PMID: 27448609]
[17]
Choi SH, Byun JH, Lim YS, et al. Diagnostic criteria for hepatocellular carcinoma <3 cm with hepatocyte-specific contrast-enhanced magnetic resonance imaging. J Hepatol 2016; 64(5): 1099-107.
[http://dx.doi.org/10.1016/j.jhep.2016.01.018] [PMID: 26820629]
[18]
Imbriaco M, De Luca S, Coppola M, et al. Diagnostic accuracy of Gd-EOB-DTPA for detection hepatocellular carcinoma (HCC): A comparative study with dynamic contrast enhanced magnetic resonance imaging (MRI) and dynamic contrast enhanced computed tomography (CT). Pol J Radiol 2017; 82: 50-7.
[http://dx.doi.org/10.12659/PJR.899239] [PMID: 28217239]
[19]
Kim BR, Lee JM, Lee DH, et al. Diagnostic performance of gadoxetic acid-enhanced liver mr imaging versus multidetector CT in the detection of dysplastic nodules and early hepatocellular carcinoma. Radiology 2017; 285(1): 134-46.
[http://dx.doi.org/10.1148/radiol.2017162080] [PMID: 28609205]
[20]
Maiwald B, Lobsien D, Kahn T, Stumpp P. Is 3-Tesla Gd-EOB-DTPA-enhanced MRI with diffusion-weighted imaging superior to 64-slice contrast-enhanced CT for the diagnosis of hepatocellular carcinoma? PLoS One 2014; 9(11): e111935.
[http://dx.doi.org/10.1371/journal.pone.0111935] [PMID: 25375778]
[21]
Marks RM, Ryan A, Heba ER, et al. Diagnostic per-patient accuracy of an abbreviated hepatobiliary phase gadoxetic acid-enhanced MRI for hepatocellular carcinoma surveillance. AJR Am J Roentgenol 2015; 204(3): 527-35.
[http://dx.doi.org/10.2214/AJR.14.12986] [PMID: 25714281]
[22]
Nishie A, Kakihara D, Asayama Y, et al. Detectability of hepatocellular carcinoma on gadoxetic acid-enhanced MRI at 3 T in patients with severe liver dysfunction: Clinical impact of dual-source parallel radiofrequency excitation. Clin Radiol 2015; 70(3): 254-61.
[http://dx.doi.org/10.1016/j.crad.2014.11.006] [PMID: 25522901]
[23]
Park MJ, Kim YK, Lee MH, Lee JH. Validation of diagnostic criteria using gadoxetic acid-enhanced and diffusion-weighted MR imaging for small hepatocellular carcinoma (<= 2.0 cm) in patients with hepatitis-induced liver cirrhosis. Acta Radiol 2013; 54(2): 127-36.
[http://dx.doi.org/10.1258/ar.2012.120262] [PMID: 23148300]
[24]
Phongkitkarun S, Limsamutpetch K, Tannaphai P, Jatchavala J. Added value of hepatobiliary phase gadoxetic acid-enhanced MRI for diagnosing hepatocellular carcinoma in high-risk patients. World J Gastroenterol 2013; 19(45): 8357-65.
[http://dx.doi.org/10.3748/wjg.v19.i45.8357] [PMID: 24363528]
[25]
Renzulli M, Biselli M, Brocchi S, et al. New hallmark of hepatocellular carcinoma, early hepatocellular carcinoma and high-grade dysplastic nodules on Gd-EOB-DTPA MRI in patients with cirrhosis: a new diagnostic algorithm. Gut 2018; 67(9): 1674-82.
[http://dx.doi.org/10.1136/gutjnl-2017-315384] [PMID: 29437912]
[26]
Tillman BG, Gorman JD, Hru JM, et al. Diagnostic per-lesion performance of a simulated gadoxetate disodium-enhanced abbreviated MRI protocol for hepatocellular carcinoma screening. Clin Radiol 2018; 73(5): 485-93.
[http://dx.doi.org/10.1016/j.crad.2017.11.013] [PMID: 29246586]
[27]
Wang JH, Chen TY, Ou HY, et al. Clinical impact of gadoxetic acid-enhanced magnetic resonance imaging on hepatoma management: A prospective study. Dig Dis Sci 2016; 61(4): 1197-205.
[http://dx.doi.org/10.1007/s10620-015-3989-x] [PMID: 26668057]
[28]
Yim SY, Park BJ, Um SH, et al. Diagnostic performance of gadoxetic acid (Primovist)-enhanced MR imaging versus CT during hepatic arteriography and portography for small hypervascular hepatocellular carcinoma. Medicine (Baltimore) 2016; 95(39): e4903.
[http://dx.doi.org/10.1097/MD.0000000000004903] [PMID: 27684824]
[29]
Yoon JH, Lee JM, Lee YJ, Lee KB, Han JK. Added Value of sequentially performed gadoxetic acid-enhanced liver MRI for the diagnosis of small (10-19 mm) or atypical hepatic observations at contrast-enhanced CT: A prospective comparison. J Magn Reson Imaging 2019; 49(2): 574-87.
[http://dx.doi.org/10.1002/jmri.26199] [PMID: 30102433]
[30]
Zhou Y, Jing X, Zhang X, et al. Combining the arterial phase of contrast-enhanced ultrasonography, gadoxetic acid-enhanced magnetic resonance imaging and diffusion-weighted imaging in the diagnosis of hepatic nodules ≤20 mm in patients with cirrhosis. Ultrasound Med Biol 2019; 45(3): 693-701.
[http://dx.doi.org/10.1016/j.ultrasmedbio.2018.10.019] [PMID: 30606633]
[31]
Yang C, Jiang H, Song B, Chen J. The diagnostic performance of version 2018 LI-RADS for hepatocellular carcinoma on Gd-EOB-DTPA enhanced MRI. Chinese J Radiol (China) 2019; 53(12): 1060-4.
[32]
Dong LW, Wang F, Luo SS, Zhao YM, Chen F, Li JJ. Differential diagnostic value of gadoxetic acid disodium enhanced 3.0T MRI for hepatic nodules in patients with liver cirrhosis. China Med Herald 2018; (31): 127-30.
[33]
Xu XL, Li XY, Lu GG. The clinical value of promethine in the enhancement of CT and MRI in patients with liver cancer. J Med Imaging (Bellingham) 2020; (03): 515-8.
[34]
Huang JL, Li LJ, Chen GX. Early hepatocellular carcinoma diagnosed by Gd-EOB-DTPA enhanced MRI combined with multi b- value DWI image. J Med Imaging (Bellingham) 2019; (08): 1354-7.
[35]
Wu J, Kang Y, Hong N, Li AQ, Wang Q. Diagnostic accuracy of Gd-EOB-DTPA-enhanced hepatobiliary phase MRI imaging combined with DW-MRI for hepatocellular carcinoma. J Third Mil Med Univ 2015; (06): 548-52.
[36]
Ding Y, Cheng CZ, Rao SX, Zeng MS. A compared study on Gd-EOB-DTPA and Gd-DTPA-enhanced MRI in detection of hepatocellular carcinoma. Chin J Gen Surg 2013; 9(28)
[37]
Liu XJ, Tang HH, Lin LL, et al. The value of Gd-EOB-DTPA-enhanced MRI in the detection of HCC. Radiol Prat 2016; (01): 26-9.
[38]
Deng J. The diagnostic value of gadoxetic acid disodium injection enhanced MRI for hepatic nodules. Chin Foreign Med Res 2015; (36): 60-1.
[39]
Jia NL, Wang SH, Li CZ. Comparison of MSCT and Gd-EOB-DTPA DCE-MRI in the diagnosis of focal liver lesions. Chin J of CT MRI 2020; 05: 5-7+17.
[40]
Li R, Yang D, Tang CL, Zhang L, Li HT, Guo DY. Comparison of the diagnostic value of hepatocellular carcinoma ≤ 3 cm in diameter in patients with chronic liver disease between contrast-enhanced ultrasound and gadolinium diethylene-triamine-pentaacetic acid-enhanced magnetic resonance imaging. Chin J Med Ultrasound 2017; (05): 386-93.
[41]
Li XQ, Zhou ZP, He SQ, Chen XP. To compare the role of Gd- EOB-DTPA dynamic contrast-enhanced MRL with multi -detector row computed tomography (MDCT) in patients with focal liver lesions. Chin J Hepatobiliary Surg 2013; (11): 815-20.
[42]
He SS. Diagnostic value of gadolinium acid two sodium enhanced MRI in cirrhotic nodules and small hepatocellular carcinoma. J Med Imaging (Bellingham) 2019; (06): 973-6.
[43]
Shi AJ, Zhang W, Yang H, Zang JL. Dynamic contrast-enhanced MRl with gadoxetate disodium in the diagnosis of cirrhotic nodules and small hepatocellular carcinoma. GD Chem 2020; (06): 81-2.
[44]
Li X, Wang R, Liang T, et al. The diagnostic value of gadoxetate-disodium enhanced magnetic resonance combined with diffusion weighted imaging for AFP-negative liver cancer. Chinese journal of CT and MRI 2019; (11): 73-6.
[45]
Ye F, Song Y, She XD, Zhang HM, Ou YH, Wu N. Hepatobiliary phase imaging with Gd-EOB-DTPA for detection and characterization of hepatocellular carcinoma in patients with chronic liver disease. Chin J Med Imaging 2015; (04): 571-5.
[46]
Fang WL, Yang QY, Zhai JC, et al. Application of Gd-EOB-DTPA enhanced MRI in the early imaging diagnosis of hepatocellular carcinoma. Hainan Med J 2017; (03): 432-4.
[47]
Cao Y, Fang XJ, Dai YL. Value of the application of MRI enhanced scan with Gd-EOB-DTPA in differentiating cirrhotic nodules from hepatocellular carcinoma. Med Sci J Cent South Chin 2020; (01): 76-9.
[48]
Xu MY, Zhang XP, Huang HY, Li CL, Lin ZQ. Gd-EOB-DTPA dynamic enhanced MRI in early imaging diagnosis of hepatocellular carcinoma. Mod Diagn Treat 2019; (04): 578-80.
[49]
Ahn SS, Kim MJ, Lim JS, Hong HS, Chung YE, Choi JY. Added value of gadoxetic acid-enhanced hepatobiliary phase MR imaging in the diagnosis of hepatocellular carcinoma. Radiology 2010; 255(2): 459-66.
[http://dx.doi.org/10.1148/radiol.10091388] [PMID: 20413759]
[50]
Akai H, Kiryu S, Matsuda I, et al. Detection of hepatocellular carcinoma by Gd-EOB-DTPA-enhanced liver MRI: Comparison with triple phase 64 detector row helical CT. Eur J Radiol 2011; 80(2): 310-5.
[http://dx.doi.org/10.1016/j.ejrad.2010.07.026] [PMID: 20732773]
[51]
Baek CK, Choi JY, Kim KA, et al. Hepatocellular carcinoma in patients with chronic liver disease: A comparison of gadoxetic acid-enhanced MRI and multiphasic MDCT. Clin Radiol 2012; 67(2): 148-56.
[http://dx.doi.org/10.1016/j.crad.2011.08.011] [PMID: 21920517]
[52]
Blondin D, Erhardt A, Crynen K, et al. Diagnosis of focal liver lesions in cirrhotic patients: Comparison of contrast-enhanced ultrasound using sulphur hexafluoride (SF6) microbubbles and MRI using Gd-EOB-DTPA. Z Gastroenterol 2011; 49(1): 23-9.
[http://dx.doi.org/10.1055/s-0029-1245781] [PMID: 21225534]
[53]
Filippone A, Cianci R, Patriarca G, Sabatino F, Tartaro A, Cotroneo AR. The value of gadoxetic acid-enhanced hepatospecific phase MR imaging for characterization of hepatocellular nodules in the cirrhotic liver. Eur J Clin Med Oncol 2010; 2(4): 1.
[54]
Golfieri R, Renzulli M, Lucidi V, Corcioni B, Trevisani F, Bolondi L. Contribution of the hepatobiliary phase of Gd-EOB-DTPA-enhanced MRI to Dynamic MRI in the detection of hypovascular small (≤ 2 cm) HCC in cirrhosis. Eur Radiol 2011; 21(6): 1233-42.
[http://dx.doi.org/10.1007/s00330-010-2030-1] [PMID: 21293864]
[55]
Granito A, Galassi M, Piscaglia F, et al. Impact of gadoxetic acid (Gd-EOB-DTPA)-enhanced magnetic resonance on the non-invasive diagnosis of small hepatocellular carcinoma: A prospective study. Aliment Pharmacol Ther 2013; 37(3): 355-63.
[http://dx.doi.org/10.1111/apt.12166] [PMID: 23199022]
[56]
Kim SH, Kim SH, Lee J, et al. Gadoxetic acid-enhanced MRI versus triple-phase MDCT for the preoperative detection of hepatocellular carcinoma. AJR Am J Roentgenol 2009; 192(6): 1675-81.
[http://dx.doi.org/10.2214/AJR.08.1262] [PMID: 19457834]
[57]
Ooka Y, Kanai F, Okabe S, et al. Gadoxetic acid-enhanced MRI compared with CT during angiography in the diagnosis of hepatocellular carcinoma. Magn Reson Imaging 2013; 31(5): 748-54.
[http://dx.doi.org/10.1016/j.mri.2012.10.028] [PMID: 23218794]
[58]
Sano K, Ichikawa T, Motosugi U, et al. Imaging study of early hepatocellular carcinoma: Usefulness of gadoxetic acid-enhanced MR imaging. Radiology 2011; 261(3): 834-44.
[http://dx.doi.org/10.1148/radiol.11101840] [PMID: 21998047]
[59]
Sugimoto K, Moriyasu F, Shiraishi J, et al. Assessment of arterial hypervascularity of hepatocellular carcinoma: Comparison of contrast-enhanced US and gadoxetate disodium-enhanced MR imaging. Eur Radiol 2012; 22(6): 1205-13.
[http://dx.doi.org/10.1007/s00330-011-2372-3] [PMID: 22270142]
[60]
Li J, Wang J, Lei L, Yuan G, He S. The diagnostic performance of gadoxetic acid disodium-enhanced magnetic resonance imaging and contrast-enhanced multi-detector computed tomography in detecting hepatocellular carcinoma: A meta-analysis of eight prospective studies. Eur Radiol 2019; 29(12): 6519-28.
[http://dx.doi.org/10.1007/s00330-019-06294-6] [PMID: 31250172]
[61]
Duncan JK, Ma N, Vreugdenburg TD, Cameron AL, Maddern G. Gadoxetic acid-enhanced MRI for the characterization of hepatocellular carcinoma: A systematic review and meta-analysis. J Magn Reson Imaging 2017; 45(1): 281-90.
[http://dx.doi.org/10.1002/jmri.25345] [PMID: 27299482]
[62]
Lee YJ, Lee JM, Lee JS, et al. Hepatocellular carcinoma: diagnostic performance of multidetector CT and MR imaging-a systematic review and meta-analysis. Radiology 2015; 275(1): 97-109.
[http://dx.doi.org/10.1148/radiol.14140690] [PMID: 25559230]
[63]
Roberts LR, Sirlin CB, Zaiem F, et al. Imaging for the diagnosis of hepatocellular carcinoma: A systematic review and meta-analysis. Hepatology 2018; 67(1): 401-21.
[http://dx.doi.org/10.1002/hep.29487] [PMID: 28859233]
[64]
Bruix J, Sherman M. Management of hepatocellular carcinoma: an update. Hepatology 2011; 53(3): 1020-2.
[http://dx.doi.org/10.1002/hep.24199] [PMID: 21374666]
[65]
Bossuyt PM, Reitsma JB, Bruns DE, et al. STARD 2015: An updated list of essential items for reporting diagnostic accuracy studies. BMJ 2015; 351: h5527.
[http://dx.doi.org/10.1136/bmj.h5527] [PMID: 26511519]
[66]
Li XQ, Wang X, Zhao DW, et al. Application of Gd-EOB-DTPA-enhanced magnetic resonance imaging (MRI) in hepatocellular carcinoma. World J Surg Oncol 2020; 18(1): 219.
[http://dx.doi.org/10.1186/s12957-020-01996-4] [PMID: 32828123]
[67]
Liu X, Jiang H, Chen J, Zhou Y, Huang Z, Song B. Gadoxetic acid disodium-enhanced magnetic resonance imaging outperformed multidetector computed tomography in diagnosing small hepatocellular carcinoma: A meta-analysis. Liver Transpl 2017; 23(12): 1505-18.
[http://dx.doi.org/10.1002/lt.24867] [PMID: 28886231]
[68]
American college of radiology. Liver imaging reporting and data system. Availalble from: https://www.acr.org/Clinical-Resources/Reporting-and-Data-Systems/LI-RADS [Accessed September 2, 2018]